Balsalazida [Spanish] en es it fr

Balsalazida [Spanish] Brand names, Balsalazida [Spanish] Analogs

Balsalazida [Spanish] Brand Names Mixture

  • No information avaliable

Balsalazida [Spanish] Chemical_Formula


Balsalazida [Spanish] RX_link

Balsalazida [Spanish] fda sheet

Balsalazida_[Spanish] FDA

Balsalazida [Spanish] msds (material safety sheet)

Balsalazida [Spanish] Synthesis Reference

No information avaliable

Balsalazida [Spanish] Molecular Weight

357.318 g/mol

Balsalazida [Spanish] Melting Point

No information avaliable

Balsalazida [Spanish] H2O Solubility

Freely soluble as disodium salt

Balsalazida [Spanish] State


Balsalazida [Spanish] LogP


Balsalazida [Spanish] Dosage Forms

Capsule (750 mg)

Balsalazida [Spanish] Indication

For the treatment of mildly to moderately active ulcerative colitis.

Balsalazida [Spanish] Pharmacology

Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine.

Balsalazida [Spanish] Absorption

Low and variable, intact balsalazide is poorly absorbed systemically.

Balsalazida [Spanish] side effects and Toxicity

A single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.

Balsalazida [Spanish] Patient Information

No information avaliable

Balsalazida [Spanish] Organisms Affected

Humans and other mammals